Gilead Sciences, Inc. (GILD)
NASDAQ: GILD · IEX Real-Time Price · USD
68.40
-0.24 (-0.35%)
At close: Jul 2, 2024, 4:00 PM
68.49
+0.09 (0.13%)
After-hours: Jul 2, 2024, 7:50 PM EDT
Gilead Sciences Employees
Gilead Sciences had 18,000 employees as of December 31, 2023. The number of employees increased by 1,000 or 5.88% compared to the previous year.
Employees
18,000
Change (1Y)
1,000
Growth (1Y)
5.88%
Revenue / Employee
$1,525,000
Profits / Employee
$26,889
Market Cap
85.22B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 18,000 | 1,000 | 5.88% |
Dec 31, 2022 | 17,000 | 2,600 | 18.06% |
Dec 31, 2021 | 14,400 | 800 | 5.88% |
Dec 31, 2020 | 13,600 | 2,600 | 23.64% |
Jan 31, 2019 | 11,000 | 1,000 | 10.00% |
Jan 31, 2018 | 10,000 | 1,000 | 11.11% |
Jan 31, 2017 | 9,000 | 1,000 | 12.50% |
Jan 31, 2016 | 8,000 | 1,000 | 14.29% |
Jan 31, 2015 | 7,000 | 900 | 14.75% |
Jan 31, 2014 | 6,100 | 1,100 | 22.00% |
Jan 31, 2013 | 5,000 | 500 | 11.11% |
Jan 31, 2012 | 4,500 | 500 | 12.50% |
Jan 31, 2011 | 4,000 | 148 | 3.84% |
Jan 31, 2010 | 3,852 | 411 | 11.94% |
Jan 31, 2009 | 3,441 | 462 | 15.51% |
Jan 31, 2008 | 2,979 | 464 | 18.45% |
Jan 31, 2007 | 2,515 | 615 | 32.37% |
Jan 31, 2006 | 1,900 | 246 | 14.87% |
Feb 28, 2005 | 1,654 | 229 | 16.07% |
Feb 27, 2004 | 1,425 | 175 | 14.00% |
Feb 28, 2003 | 1,250 | 250 | 25.00% |
Feb 28, 2002 | 1,000 | 150 | 17.65% |
Feb 28, 2001 | 850 | 90 | 11.84% |
Dec 31, 1999 | 760 | 467 | 159.39% |
Dec 31, 1998 | 293 | 4 | 1.38% |
Dec 31, 1997 | 289 | 41 | 16.53% |
Dec 31, 1996 | 248 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
HCA Healthcare | 310,000 |
Medtronic | 95,000 |
Cigna | 72,500 |
GSK | 70,212 |
McKesson | 51,000 |
Boston Scientific | 48,000 |
Bristol-Myers Squibb Company | 34,100 |
Zoetis | 14,100 |
GILD News
- 4 days ago - Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields - Benzinga
- 12 days ago - Gilead Stock Surges on Strong Results in HIV Drug Study - Investopedia
- 12 days ago - Gilead's twice-yearly shot to prevent HIV succeeds in late-stage trial - CNBC
- 12 days ago - Gilead's HIV prevention treatment found 100% effective in late-stage trial - Market Watch
- 12 days ago - Gilead's long-acting HIV drug superior to daily pill Truvada in study - Reuters
- 12 days ago - Gilead's Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention - Business Wire
- 18 days ago - Gilead Stock Gains. It's Trying to Get Into the Obesity Drug Game. - Barrons
- 18 days ago - New Kite Clinical Research and Real-World Evidence for Yescarta® Demonstrate Benefit From Earlier Lines of Treatment - Business Wire